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 The glaucomas comprise a group of heterogeneous optic
neuropathies with a complex genetic basis. If untreated, these
neuropathies lead to optic nerve damage along with a pro-
gressive loss of vision [1,2]. According to latest estimates,
glaucoma affects about 67 million people worldwide [3] and
1.5 million in India [4]. Among the various glaucoma sub-
types, primary open angle glaucoma (POAG) is more com-
mon and accounts for half of these cases [5]. Seven chromo-
somal loci (GLC1A-GLC1G) have so far been implicated in
POAG [6-12], of which three genes, myocilin (MYOC) on
GLC1A (1q32) [13], optineurin (OPTN) [14] on GLC1E
(10p25), and WDR-36 on GLC1G (5q22.3) [12] have been
characterized. In addition, a few other chromosomal loci have
been mapped for POAG through genome-wide scans on 2q,
9q, 10p, 14q, 15q, and 22p that do not overlap with the previ-
ously implicated loci [15-17]. Through bioinformatic analy-
sis, the Noelin family of genes has also been suggested to be
involved in ocular pathogenesis leading to glaucoma [18].
Among the three glaucoma genes, the potential role of
MYOC has been well documented in juvenile and adult-onset
POAG [19]. Globally, MYOC mutations account for 2-5% of
all POAG cases [1,2,19]. On the other hand, defects in OPTN
have been implicated in normal tension glaucoma (NTG) and
mild to moderate forms of late-onset POAG [14,20]. How-
ever, mutations in both MYOC and OPTN genes could have
considerable overlaps in phenotypic expressions.
An initial report on 52 POAG families demonstrated the
involvement of OPTN mutations in 16.7% along with an ad-
ditional risk to 13.6% of familial and sporadic cases due to
the intragenic SNPs [14]. Following this discovery, a large
number of studies were undertaken to identify the defects in
OPTN causal to NTG and POAG [21-31]. One such study
screened 1,048 patients for variations previously associated
with glaucoma [21]. Among the previously reported mutations
[14], they detected one individual with familial NTG and Brit-
ish ancestry to have the Glu50Lys mutation. The Arg545Gln
was described as a polymorphism that does not cause disease
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and the previously reported frame-shift mutation was not de-
tected in any of their patients. Additionally, there are contra-
dicting reports from different ethnic groups particularly from
Asia that investigated the involvement of OPTN in POAG and/
or NTG [27-30], but none from India. The present study was
therefore aimed at understanding the possible role of OPTN
in the causation of POAG among Indian patients from differ-
ent parts of the country.
METHODS
Selection of cases:  The study protocols adhered to the tenets
of the Declaration of Helsinki and was approved by the Insti-
tutional Review Board. Two hundred Indian patients (mean
age 48.7±16.8) with or without a family history of POAG pre-
senting at the LV Prasad Eye Institute, Hyderabad, Eye Care
& Research Center, and Regional Institute of Ophthalmology,
Kolkata, were recruited. All the POAG cases had an elevated
intraocular pressure of >21 mm Hg and/or glaucomatous disc
changes in the presence of typical field defects, along with an
open angle on gonioscopy and no other secondary causes.
Cases with a history of inflammation, ocular trauma, ocular
hypertension, and normal tension glaucoma were excluded
[32]. Two hundred ethnically matched normal individuals
(mean age 56.2±12.1) without any signs or symptoms of glau-
coma or other associated ocular or systemic diseases served
as controls.
Collection of samples and DNA analysis:  Blood samples
were collected in EDTA by venipuncture with prior informed
consent from the POAG patients and controls. Genomic DNA
was prepared using the conventional phenol-chloroform ex-
traction method. The coding region of OPTN (NM_021980;
contig containing OPTN: NT_077569) was amplified by poly-
merase chain reaction (PCR) using exon-specific primers (de-
signed and kindly provided by Dr. Mansoor Sarfarazi, Uni-
versity of Connecticut, Farmington, CT). PCR was carried out
in a total volume of 25.0 µl containing 50-100 ng genomic
DNA, 0.4 µM of each primer, 0.2 mM of each dNTP, appro-
priate concentration of MgCl2, and 0.5 unit of Taq polymerase
(Invitrogen, Carlsbad, CA) in a GeneAmp-9700 thermocycler
(PE Applied Biosystem, Foster City, CA).
Mutation screening by SSCP and dHPLC:  Mutation
screening was done by single-strand conformation polymor-
phism (SSCP) of the PCR amplicons in 8% non-denaturing
polyacrylamide gels run at different temperatures with and
without glycerol. Prior to loading, amplicons were denatured
at 95 °C for 5 min and snap chilled on ice to prevent reannealing
of the single stranded product. Electrophoresis was performed
at a constant 160 volts for 18-22 h, depending on the sizes of
the amplicon. Following electrophoresis the gels were silver
stained to visualize the bands. Samples exhibiting band shifts
were further analyzed by direct sequencing.
The SSCP variants were screened by denaturing high-per-
formance liquid chromatography (dHPLC) in the Wave Ana-
lyzer (Transgenomic Inc., Omaha, NB) for high-throughput
screening in additional patient and control samples. Prior to
loading, the samples were denatured at 96 °C for 5 min and
were gradually cooled down to 65 °C to facilitate heterodu-
plex formation. The melting temperatures were calculated from
the WAVEMAKER™ software (version 4.1) and were based
on fragment length, sequence, and the position of the variant
in the amplicon. Samples were run under partially denaturing
conditions and the elution of heteroduplex peaks was moni-
tored from the chromatogram.
DNA sequencing:  The variants observed in SSCP/dHPLC
were characterized through bi-directional sequencing of the
amplicon. The PCR amplicons were column-purified using
the Qiagen PCR-purification kit (Qiagen, Hilden, Germany),
and sequencing was performed on an ABI Prism 3100 DNA
sequencer using the BigDye chemistry. Nucleotide changes
were detected from the chromatogram by comparing with the
normal OPTN gene sequence available in the database by
Pairwise BLAST [33].
Restriction enzyme digestion:  Nucleotide variants iden-
tified by DNA sequencing, that altered restriction sites, were
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TABLE 1. NUCLEOTIDE CHANGES IN THE OPTN GENE IN INDIAN POAG PATIENTS
                                                                          Observed genotypes
                                                                          (wt,wt/wt,mt/mt,mt)
 Nucleotide    Position                     Restriction    Amino acid   -----------------------
   change      in gene     Mutation/SNP      site (+/-)      change      Patients     Controls
------------   --------   ---------------   ------------   ----------   ----------   ----------
c.428 G>A      Exon 4     SNP (rs2234968)   HpyCh4IV (-)   Thr34Thr     134/61/  5   106/83/11
c.619 T>A      Exon 5     SNP               StuI (+)       Met98Lys     178/22/  0   189/11/ 0
c.879-10 G>A   Intron 6   SNP                                           197/ 3/  0   100/ 0/ 0*
c.879-5 C>T    Intron 6   SNP (rs2244380)                                12/55/133     6/28/66*
c.1960 G>A     Exon 16    Mutation          AciI (-)       Arg545Gln    194/ 6/  0   200/ 0/ 0
c.773 G>A      Exon 6     Novel SNP                        Arg149Arg     99/ 0/  1    99/ 1/ 0*
c.1054 C>A     Exon 10    Novel SNP         MnlI (-)       Asn303Lys    199/ 1/  0   194/ 6/ 0
Nucleotide changes in the OPTN gene in Indian POAG patients are essentially nonpathogenic. In the “Restriction site (+/-)” column, the sign
indicates the creation or abolition of a restriction site for HpyCh4IV (HpyCh4IV), StuI (StuI), AciI (AciI), or MnlI (MnlI). The terms “wt” and
“mt” indicate the wild type allele and the mutant allele, respectively. The asterisks indicate that these intronic and synonymous variants were
screened in 100 normal controls. Observed genotypes were scored to estimate the potential association of specific nucleotide variants with the
phenotypes (i.e., POAG or normal). While no significant variation was observed for any SNP, the reported mutation (Arg545Gln) was de-
tected only in six heterozygous patients, but not in the controls.
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screened in additional POAG patients and control samples by
digesting the amplicon with appropriate restriction enzyme
(Table 1) as per the manufacturer’s protocol (New England
BioLabs, Beverly, MA). DNA fragments in the digest were
separated by electrophoresis in 6% polyacrylamide gels,
stained with ethidium bromide, and visualized under an UV
transilluminator. Alleles were scored based on the band pat-
terns in the gel.
RESULTS & DISCUSSION
 Screening of OPTN in a pool of 200 unrelated POAG pa-
tients of Indian origin revealed seven different nucleotide vari-
ants (Table 1) of which only the Arg545Gln was a potential
mutation that was originally reported by Rezaie et al. [14], in
2002. Among the other variants, the Met98Lys was previously
reported to be a risk factor in certain populations [22,24] and
the remaining comprised of five innocuous single nucleotide
changes. Our results emphasize a limited involvement of OPTN
in Indian POAG patients similar to most other studies
[23,26,30,31].
Arg545Gln as a potential mutation:  We detected a nucle-
otide variant c.1960G>A in 6/200 POAG patients (3.0%) that
represented a missense mutation Arg545Gln in exon 16 in the
present study. This variant creates a restriction site for AciI
and was absent in 400 normal chromosomes. Interestingly, all
of these patients (6) were from eastern India, and two of them
had a juvenile onset of the disease symptoms. Haplotypes gen-
erated through intragenic single nucleotide polymorphisms
(SNPs) indicated multiple independent origins for the
Arg545Gln variation (data not shown). Although Arg545Gln
does not belong to any known protein domain of OPTN, it is
located near the zinc finger motif, the latter being normally
seen in transcription factors.
 This variant was initially identified only in a patient and
was absent in normal controls that led investigators to term it
as a mutation [14]. Since then there has been multiple reports
on various ethnic groups contradicting the status of this vari-
ant as a pathogenic mutation (Table 2). This mutation has not
been observed in any other patient of Caucasian origin from
Canada, the United States, Germany, and Australia
[21,25,26,31]. As evident from Table 2, the Arg545Gln muta-
tion has been observed predominantly in Asian populations,
with varying frequencies. A large series of 1,048 patients from
the United States [21] and 66 patients from Canada [25] ob-
served the Arg545Gln only in 12 NTG patients (3.4%) of Japa-
nese and one JOAG patient of Chinese origins, respectively.
These variants were also observed in Japanese and Chinese
control chromosomes, although the differences were not sta-
tistically significant. Similarly another study on 119 POAG
subjects from China observed this variant in almost equal fre-
quencies among the patients (6.7%) and controls (8.7%) [27].
A recent report on Japanese patients observed the
Arg545Gln change only in one NTG patient and not in the
POAG cases or controls [30], similar to the initial report of
Rezaie et al. [14]. However, two large studies from Japan re-
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TABLE 2. DISTRIBUTION OF THE ARG545GLN VARIANT
                 Variants present
                    (%, total)
             ------------------------
Population    Patients      Controls    References
----------   -----------   ----------   ----------
Australia    0.00   (27)   0.00  (94)      [26]
Canada       1.51   (66)   1.63 (184)      [25]
Germany      0.00  (112)   0.00 (100)      [31]
UK           0.00  (315)   0.00  (95)      [22]
USA          0.00   (86)   0.00  (80)      [23]
USA          0.09 (1048)   1.19 (251)      [21]
USA          2.17   (46)   0.00 (100)      [14]
China        6.72  (119)   8.73 (126)      [27]
Japan        0.06  (154)   0.00 (100)      [30]
Japan        6.32  (411)   5.04 (218)      [29]
Japan        6.38  (313)   5.10 (196)      [28]
India        3.00  (200)   0.00 (200)    Present
                                          study
Variable distribution of Arg545Gln in open angle glaucoma (OAG)
patients and controls in different population groups of the world.
Among the population groups from consisting mostly of Caucasians
a single study [14] reported the presence of the variant allele, coding
for 545Gln, among the OAG patients. However, the frequencies of
the variant allele in the OAG patients and controls were comparable
among east Asians except for one study [30] that observed this vari-
ant in an NTG patient and not in the controls. Our study on Indian
POAG patients identified the variant allele only among the patients
similar to the original report [14] that implicated OPTN in open angle
glaucoma.
TABLE 3. FREQUENCY DISTRIBUTION OF THE MET98LYS VARIANT
ALLELE
                 Patients
             ------------------
Population   POAG (%)   NTG (%)   Controls (%)   References
----------   --------   -------   ------------   ----------
Australia       7.4       0.0          3.2          [26]
Canada         12.2       0.0          3.9          [25]
France          4.6       0.0          4.5          [24]
Germany         0.0       6.3          7.0          [31]
Morocco        10.7       0.0          8.3          [24]
UK              4.4      10.6          3.2          [22]
USA             1.8      11.8          4.3          [14]
USA             5.1       5.3          7.2          [21]
USA             9.0       0.0         10.0          [23]
China          28.6       0.0         24.6          [27]
Japan          16.9      15.4          5.0          [30]
Japan          17.0      22.1         16.5          [29]
Japan          13.3      19.6         13.8          [28]
India          11.0       0.0          5.5         Present
                                                   study
Frequency distribution of variant alleles coding for Met98Lys in
POAG and NTG patients in different population groups of the world.
The table highlights the variability in the reported studies on the rela-
tive frequency of the allele coding for 98Lys among the population
groups consisting mostly of Caucasians, east Asian, and south Asian.
Such variability in the allelic distribution might be due to different
gene pools in the population groups which determine the interaction
of OPTN with other proteins contributing to the pathophysiology of
the disease.
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ported strikingly similar frequencies of this variant in cases of
POAG, NTG, and controls [28,29]. It has been claimed that
the Arg545Gln mutation could largely be a polymorphism that
does not cause disease in Asian populations [21,27], although
the present study did not observe this variant in unrelated nor-
mal individuals. Unlike other studies, our results indicate a
significant association of Arg545Gln in POAG (p<0.05). Vari-
able penetrance of the OPTN variant in different ethnic popu-
lations suggests potential involvement of other modifying loci,
which might differ from one population to the other. Further,
it highlights the importance of screening this variant in Indian
POAG populations to establish its potential role in causation
of POAG.
Is the Met98Lys a potential risk factor?:  The nucleotide
variant c.619T>A (Met98Lys) was detected both in patients
and controls by restriction digestion of the PCR amplicon with
StuI as described earlier [22] followed by confirmation of the
variants by direct sequencing. The frequency of the minor al-
lele among the patients (0.05) and controls (0.03) was statisti-
cally not significant. None of the individuals screened exhib-
ited this variant in the homozygous condition (Table 1).
The Met98Lys variant was initially identified as an “at-
tributable risk factor” as it was observed in significantly higher
frequencies in patients (13.6%) than control chromosomes
(2.1%) [14]. However, the other studies from American popu-
lations did not reveal any significant differences in the fre-
quencies of the Met98Lys variant among the patients and con-
trols (Table 3). The large multi-ethnic study on 1,048 patients
did find a significant association of Met98Lys (p=0.01) among
the 247 Japanese NTG patients in their subset compared to
Japanese control subjects (n=89), but the sample size in this
subset was relatively small to perform a case-control study
[21]. Similar results were replicated from a study among Japa-
nese patients that claimed the Met98Lys variant to be a risk
factor in POAG (p=0.009) and NTG (p=0.029), respectively
[30]. Another independent study from Japan observed a rela-
tively higher frequency of the Met98Lys variant allele in 217
NTG (22.1%) compared to 194 POAG (17.0%) patients and
controls (16.5%), although the differences were not signifi-
cant (p=0.139 for NTG and p=0.893 for POAG) [29]. An-
other Japanese study did not support this conclusion [28].
Later Met98Lys was reported to be a modifier of initial
IOP in POAG patients [24]. Another study involving POAG
and NTG patients from London showed that Met98Lys was
associated specifically with NTG but not with HTG [22]. In
light of these observations, a study comprising of only NTG
patients is warranted to test for any causal association among
Indian patients.
Other nucleotide variants:  A novel heterozygous change
was identified at c.1054C>A causing a substitution of aspar-
agine by lysine (Asn303Lys) in a sporadic POAG case from
eastern India that abolished a restriction site for MnlI. The
segregation of mutant alleles could not be confirmed because
DNA samples from his parents were not available. However
this nonconservative change was also seen in 6 ethnically
matched normal controls from eastern India. Although the wild
type residue of this variant is highly conserved across species
(data not shown), it is unlikely to play a potential role in the
disease pathogenesis. However in absence of a functional as-
say we cannot comment any further on this issue.
The remaining four nucleotide changes were either
intronic or silent changes that are unlikely to be involved in
the pathogenesis. A silent change at c.428G>A (Thr34Thr) was
detected in exon 4 that abolishes a restriction site for
HpyCh4IV. In our series, the frequency of the variant allele
among the patients (0.18) and controls (0.26) was not signifi-
cant (p>0.5). This change was found in almost all the studies
undertaken across different populations including the Asians
[14,27-30].
We observed two intronic variants upstream of exon 7 at
IVS6-10G>A and IVS6-5C>T. As these changes did not cre-
ate or abolish any restriction site, the entire pool of patients
and controls were sequenced for this locus and the frequen-
cies of the variant allele were identical for patients and con-
trols (Table 1). Since both changes were intronic, not predicted
to create cryptic splice sites and two variants were already
reported as SNPs [27], its role in causation of the disease could
be ruled out. However, like the silent change in exon 4
(Thr34Thr), the more frequent SNP (IVS6-5C>T) could be
used as an informative marker in POAG pedigrees.
The present study also did not observe significant asso-
ciation to any SNPs in patients and controls, similar to most
other studies [21,25-28,31]. As OPTN is commonly associ-
ated with NTG, it seems reasonable that further studies on the
involvement of OPTN in glaucoma should be conducted, spe-
cifically on NTG patients. While there are some studies ex-
hibiting association of OPTN to POAG and NTG from differ-
ent ethnic groups of Asia [27,29], its major role in the disease
process leading to POAG is still debatable. Despite finding a
putative mutation (Arg545Gln), the present study did not show
any evidence for the involvement of OPTN in the pathogen-
esis of POAG. It is worth noting that unlike the mutation spec-
trum in MYOC causing POAG [19], there are relatively fewer
mutations in OPTN that would lead to POAG or NTG [20].
By and large the nucleotide variants observed across popula-
tions have largely been SNPs that are infrequently associated
with the disease phenotype [20-31]. It is evident that OPTN
exhibits wide variations in different ethnic groups and may be
involved in POAG and primarily with NTG through a com-
plex biochemical pathway that merits functional studies of the
OPTN protein.
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